Actuate Therapeutics, Inc. (ACTU)
NASDAQ: ACTU · Real-Time Price · USD
0.9837
-0.0463 (-4.50%)
At close: Sep 15, 2026, 4:00 PM EDT
1.020
+0.036 (3.69%)
After-hours: Sep 15, 2026, 7:43 PM EDT
Actuate Therapeutics Employees
Actuate Therapeutics had 12 employees as of December 31, 2025. The number of employees increased by 2 or 20.00% compared to the previous year.
Employees
12
Change (1Y)
2
Growth (1Y)
20.00%
Revenue / Employee
n/a
Profits / Employee
-$1,704,484
Market Cap
23.62M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 12 | 2 | 20.00% |
| Dec 31, 2024 | 10 | 5 | 100.00% |
| Sep 30, 2024 | 11 | 6 | 120.00% |
| Jun 30, 2024 | 11 | - | - |
| Mar 31, 2024 | 10 | - | - |
| Dec 31, 2023 | 5 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Evaxion | 46 |
| Longeveron | 38 |
| ABVC BioPharma | 19 |
| Quantum BioPharma | 17 |
| Atossa Therapeutics | 16 |
| Tvardi Therapeutics | 12 |
| Cocrystal Pharma | 10 |
| NanoViricides | 7 |
ACTU News
- 1 day ago - Actuate Therapeutics Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts
- 6 days ago - Actuate to Present at the H.C. Wainwright 28th Annual Global Investment Conference - GlobeNewsWire
- 6 days ago - Actuate Announces Promising Preclinical Data Showing Synergistic Activity of Elraglusib in Combination with RAS Inhibitors Zoldonrasib and Daraxonrasib - GlobeNewsWire
- 4 weeks ago - Actuate Therapeutics Quarterly report: Q2 2026 - Filings
- 4 weeks ago - Actuate Therapeutics Slides: Corporate presentation - Filings
- 6 weeks ago - Actuate Therapeutics initiated with a Buy at Rodman & Renshaw - TheFly
- 3 months ago - Actuate Therapeutics' Elraglusib Selected for Evaluation in BEACON2 Trial for High-Risk Pediatric Neuroblastoma - GlobeNewsWire
- 3 months ago - Actuate Therapeutics Announces ASCO Poster Presentations Demonstrating Compelling Clinical and Biomarker Data for Elraglusib in First-Line Metastatic Pancreatic Cancer - GlobeNewsWire